The earnings call presented a strong performance with significant revenue and EBITDA growth, driven by high client retention and successful new product launches. However, potential challenges include dependency on integrated programs and tougher future revenue comparisons.

Company Guidance

During Doximity, Inc.'s fiscal 2025 third quarter earnings call, the company reported impressive financial performance with $169 million in revenue, marking a 25% year-on-year growth and a 10% beat from the high end of their guidance range. The top twenty clients demonstrated significant growth, with a net revenue retention rate of 122% on a trailing twelve-month basis. The adjusted EBITDA margin was at a record 61%, translating to $102 million, a 39% year-on-year increase. Doximity's network engagement reached new heights, with over one million unique active prescribers utilizing the news feed and 610,000 using workflow tools. The company's new point of care and formulary products saw over 100% growth, contributing to 20% of pharmaceutical sales. For the fourth fiscal quarter of 2025, revenue is expected to be between $132.5 million and $133.5 million, with an adjusted EBITDA margin projected at 47%. For the full fiscal year, the revenue is anticipated to range between $564.6 million and $565.6 million, with an adjusted EBITDA margin of 54%.

Significant Revenue Growth

Doximity, Inc. reported $169 million in revenue for Q3 FY2025, marking a 25% year-on-year growth and a 10% beat from the high end of their guidance range.

Record Adjusted EBITDA Margin

The company achieved a record adjusted EBITDA margin of 61%, or $102 million, which was up 39% year-on-year and 21% above the high end of guidance.

Top Clients Showing Strong Growth

The top twenty clients grew 122% on a trailing twelve-month basis, reflecting strong client retention and expansion.

Strong Engagement and Network Growth

Unique active users reached new heights with double-digit percent growth year-on-year. The AI tools saw over 1.8 million prompts, growing rapidly.

Successful New Product Launches

New point of care and formulary products grew over 100% in Q3, accounting for over 20% of pharmaceutical sales.

Incremental Commercial Achievements

Doximity's commercial initiatives, including new products, integrated programs, and the client portal, contributed to strong calendar year-end sales.

---

Doximity (DOCS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

DOCS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
May 20, 2025	2025 (Q4)	0.27 / -	0.25	―	―	―
Feb 06, 2025	2025 (Q3)	0.34 / 0.45	0.29	55.17% (+0.16)	―
Nov 07, 2024	2025 (Q2)	0.26 / 0.30	0.22	36.36% (+0.08)	―
Aug 08, 2024	2025 (Q1)	0.22 / 0.28	0.19	47.37% (+0.09)	―
May 16, 2024	2024 (Q4)	0.20 / 0.25	0.2	25.00% (+0.05)	―
Feb 08, 2024	2024 (Q3)	0.24 / 0.29	0.22	31.82% (+0.07)	―
Nov 09, 2023	2024 (Q2)	0.17 / 0.22	0.17	29.41% (+0.05)	―
Aug 08, 2023	2024 (Q1)	0.14 / 0.19	0.14	35.71% (+0.05)	―
May 16, 2023	2023 (Q4)	0.17 / 0.20	0.21	-4.76% (>-0.01)	―
Feb 09, 2023	2023 (Q3)	0.18 / 0.22	0.29	-24.14% (-0.07)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

DOCS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Feb 06, 2025	$58.26	$79.23	+35.99%
Nov 07, 2024	$43.42	$58.25	+34.15%
Aug 08, 2024	$25.66	$35.60	+38.74%
May 16, 2024	$23.74	$28.03	+18.07%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---